
CARDIOLOGY ROUNDUP: Canaglifozin Approved, MI in the Cold, PIVOTAL Results
A curated selection of the top stories and editor’s picks from the DocWire News Cardiology section over the last week.
—-
FDA Approves Type 2 Diabetes Treatment to Help Prevent Cardiovascular Risks
The FDA has recently approved canagliflozin (Invokana) for the reduction of cardiovascular-related events such as heart attack and stroke in adults with type 2 diabetes mellitus.
https://proddocwire.wpengine.com/docwire-pick/fda-canagliflozin-type-2-diabetes/
PIVOTAL: High-dose Iron in Hemodialysis Noninferior to Low-dose Regimen
A UK study showing that high-dose intravenous serum iron regimen was did not significantly differ from that of a low-dose regimen in patients undergoing hemodialysis.
https://proddocwire.wpengine.com/cardiology/high-dose-intravenous-iron-regimen/
EXCLUSIVE VIDEO: Ajay Kirtane, MD, Talks ECLIPSE Trial and the OPTIMUM Registry
DocWire News talks with interventional cardiology Ajay Kirtane, MD, about the design and expectations of the ECLIPSE trial and the OPTIMUM registry.
https://proddocwire.wpengine.com/docwire-pick/ajay-kirtane-md-optimum-registry/
10 Innovations to Watch For in 2019
The Cleveland Clinic has released its definitive guide on what to look out for in the medical sciences next year.
https://proddocwire.wpengine.com/future-of-medicine/10-innovations-to-watch-for-in-2019/
Myocardial Infarction More Likely to Occur in Colder Weather
Bundle up out there! Here are some data suggesting an association between lower air temperatures and an increased risk for myocardial infarction.
https://proddocwire.wpengine.com/docwire-pick/myocardial-infarction-colder-weather/